跳轉至內容
Merck
全部照片(1)

重要文件

檢視所有文件

A-008

Supelco

S(+)-苯丙胺(右旋安非他明)标准液 溶液

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

同義詞:

右旋苯丙胺

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C9H13N
CAS號碼:
51-64-9
分子量：:
135.21
MDL號碼:
MFCD00133300
分類程式碼代碼:
41116107
PubChem物質ID:
329770571
NACRES:
NA.24

等級

certified reference material

形狀

liquid

特點

SNAP-N-SPIKE®. SNAP-N-SHOOT®

包裝

ampule of 1 mL

製造商／商標名

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIB (Portugal)

濃度

1.0 mg/mL in methanol

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

應用

forensics and toxicology

形式

single component solution

儲存溫度

−20°C

SMILES 字串

C[C@H](N)Cc1ccccc1

InChI

1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1

InChI 密鑰

KWTSXDURSIMDCE-QMMMGPOBSA-N

基因資訊

human ... SLC18A2(6571)

一般說明

苯丙胺是在多动症治疗药物（例如Adderall®、Vyvanse®和ProCentra®）中发现的一种苯乙胺类兴奋剂。苯丙胺因其兴奋剂的作用，而作为性能增强剂和非法药物被娱乐性地使用。此款Snap-N-Spike®溶液经过认证，适用于尿液药物检测、临床毒理学、法医分析以及通过LC-MS/MS或GC/MS法进行的异构体鉴定。

法律資訊

Adderall is a registered trademark of Richwood Pharmaceutical Company, Inc.
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
ProCentra is a registered trademark of Outlook Pharmaceuticals, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Vyvanse is a registered trademark of Shire, LLC

相關產品

產品號碼
描述
訂價

A-016

(±)-苯丙胺-d 11 溶液, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-050

6种他明类混标 CRM 溶液, 250 μg/mL each component in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-002

(±)-Amphetamine-d5 (deuterium label on ring) solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-005

(±)-苯丙胺-d5标准液 CRM 溶液, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-007

(+/-)-苯丙胺标准液 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-013

(±)-苯丙胺-d5标准液 CRM 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-017

(±)-Amphetamine-d8 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-018

(±)-Amphetamine-d8 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-019

(±)-安非他明-D11标准液 CRM 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-044

(±)-苯丙胺-d 6标准液 溶液, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-045

(±)-苯丙胺-d 6标准液 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-049

R(-)-苯丙胺(左旋安非他命)标准液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

E-018

(±)-N-Ethylamphetamine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

L-026

Lisdexamfetamine dimesylate solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

L-028

赖氨苯丙胺-D4二甲磺酸盐 溶液, 100 μg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

P-050

PMA hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

A-212

(±)-Amphetamine-13C6 hydrochloride solution, 100 μg/mL in methanol ((as free base)), certified reference material, ampule of 1 mL, Cerilliant®

訊號詞

Danger

危險分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

標靶器官

Eyes,Central nervous system

儲存類別代碼

3 - Flammable liquids

水污染物質分類（WGK）

WGK 2

閃點（°F）

49.5 °F - closed cup

閃點（°C）

9.7 °C - closed cup

從最近期的版本中選擇一個：

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助，請聯絡 客戶支援

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

J H Check et al.
Clinical and experimental obstetrics & gynecology, 40(2), 227-228 (2013-08-27)
To further investigate the efficacy of treatment of interstitial cystitis that had been refractory to standard treatment with sympathomimetic amines. Dextroamphetamine sulfate sustained release capsules up to 30 mg per day were prescribed in women with refractory painful bladder syndrome/interstitial
Sanders A McDougall et al.
Pharmacology, biochemistry, and behavior, 104, 154-162 (2013-01-31)
The early ontogeny of D-amphetamine-induced one-trial behavioral sensitization was characterized using male and female preweanling and preadolescent rats. In Experiment 1, rats were injected with saline or D-amphetamine (1, 4, or 8mg/kg) in activity chambers or the home cage on
J H Check et al.
Clinical and experimental obstetrics & gynecology, 40(2), 284-285 (2013-08-27)
Sympathetic nervous system hypofunction has been found to be associated with motility disorders of the bowel, including gastroparesis, pseudointestinal obstruction, and esophageal motility disorders. These disorders respond to sympathomimetic amine therapy. The purpose of this study was to see if
Greg W Mattingly et al.
BMC psychiatry, 13, 39-39 (2013-01-30)
Despite the overall high degree of response to pharmacotherapy, consensus is lacking on how to judge clinical response or define optimal treatment/remission when treating adults with attention-deficit/hyperactivity disorder (ADHD). This study examined clinical response and symptomatic remission in analyses of
Joel L Young
Postgraduate medicine, 125(1), 162-168 (2013-02-09)
Fatigue is commonly reported in the primary care setting; however, its cause is often unclear. This article presents 3 cases involving patients with chronic fatigue syndrome who responded poorly to treatment. After clinical evaluation, all patients were found to meet
查看所有相關論文

文章

LC/MS Analysis of Amphetamine Enantiomers on Astec CHIROBIOTIC® V2 in Urine after Solid Phase Extraction (SPE) using Supel™-Select SCX

Shown here is the chiral separation of amphetamine enantiomers under MS-compatible conditions on Astec CHIROBIOTIC® V2 after extraction from urine using Supel™-Select SCX SPE 96-well plates. The highest grade mobile phase solvents and additives were used to supply low background interference and low particulate contaminants for robust, trouble-free operation. Cerilliant CRMs provided reliable identification and quantification.

LC/MS Analysis of Amphetamine Enantiomers on Astec CHIROBIOTIC® V2 in Urine after Solid Phase Extraction (SPE) using Supel™-Select SCX

Separation of S(+)-Amphetamine (dextro-Amphetamine) solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; R(-)-Amphetamine (levo-Amphetamine), 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material

條款

Accurate Biological Testing for Amphetamine and Methamphetamine Abuse Using Chiral HPLC and MS Detection

Optimized sample prep and chiral chromatography methods for the LC/MS analysis of these drug enantiomers in urine

Biological Testing for Amphetamine and Methamphetamine Abuse

In this study, optimized methods are presented for sample preparation and chiral chromatography for the LC/MS analysis of amphetamine and methamphetamine enantiomers in urine.

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務